Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jul 12, 2026

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System
06:23

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System

Published on: January 12, 2017

Bladder cancer biomarkers: current developments and future implementation.

Alonso Alvarez1, Vinata B Lokeshwar

  • 1Department of Urology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida 33101, USA.

Current Opinion in Urology
|September 1, 2007
PubMed
Summary

Despite advancements in bladder cancer biomarkers, including new genomic markers, clinical acceptance remains low. High standards for accuracy and patient preference for reliable diagnosis delay widespread adoption in urology.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Novel Molecular Signatures Selectively Predict Clinical Outcomes in Colon Cancer.

Cancers·2025
Same author

Natural history of bladder cancer: Validation of the multiple pathway model in multi-omics era.

Urologic oncology·2025
Same author

Protein-Based Predictive Biomarkers to Personalize Neoadjuvant Therapy for Bladder Cancer-A Systematic Review of the Current Status.

International journal of molecular sciences·2024
Same author

Targeting Chemoresistance in Advanced Bladder Cancers with a Novel Adjuvant Strategy.

Molecular cancer therapeutics·2024
Same author

Targeting Chemoresistance in Advanced Bladder Cancers with a Novel Adjuvant Strategy.

Molecular cancer therapeutics·2024
Same author

Teaching an Old Drug a New Trick: Targeting Treatment Resistance in Genitourinary Cancers.

Journal of cellular signaling·2024

Area of Science:

  • Uro-oncology
  • Biomarker discovery
  • Genomic technology

Background:

  • Bladder cancer biomarker development has advanced significantly.
  • Current biomarkers have not met physician and patient expectations for accuracy and invasiveness.
  • Patients prioritize diagnostic accuracy over less-invasive tests.

Purpose of the Study:

  • To review the latest developments in bladder cancer biomarkers.
  • To highlight markers developed in the past year.
  • To discuss the high standards hindering clinical implementation.

Main Methods:

  • Review of recent literature on bladder cancer biomarkers.
  • Inclusion of markers developed within the last year.
  • Analysis of genomic technologies and DNA methylation studies.

More Related Videos

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

Related Experiment Videos

Last Updated: Jul 12, 2026

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System
06:23

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System

Published on: January 12, 2017

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

Main Results:

  • New markers include soluble Fas, urothelial carcinoma-associated 1, and human chorionic gonadotropin beta type II genes.
  • Genomic technology contributes significantly to marker development.
  • Updates on known markers, hematuria screening, DNA methylation, and patient perspectives were discussed.

Conclusions:

  • Bladder cancer biomarkers face intense scrutiny despite good performance.
  • New findings and characteristics have not led to widespread clinical acceptance.
  • Implementation in urologic practice is delayed due to high standards.